FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment

Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.

Leave a Reply

Your email address will not be published. Required fields are marked *